Law360, New York (December 20, 2005, 12:00 AM ET) -- Extending the drawn-out legal row over generic Wellbutrin, a subsidiary of Andrx Pharmaceuticals LLC has sued British rival GlaxoSmithKline PLC, alleging the company’s current formula for the antidepressant infringes Andrx’s patent.
The complaint, filed in the U.S. District Court for the Southern District of Florida, also names Glaxo subsidiary SmithKline Beecham Corp. It points to the defendant’s extended-release, 150 mg doses as the source of infringement.
Andrx applied for the patent in the case in May 2003, and it was issued in June 2005. It covers...
Andrx, Glaxo In New Row Over Wellbutrin
To view the full article, take a free trial now.
